9 completed, 1 withdrawn. 9 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow GLA-SE: new trials by email Literature Review of GLA-SE trials Research Report on GLA-SE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy FOLFOX regimen, Nivolumab, Ipilimumab - Colorectal Cancer Metastatic | Phase 1 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2019-06-04 | 2020-02-17 | |
| Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted PAMVAC, Alhydrogel, GLA-SE - Malaria, Antepartum | Phase 1 | Completed | University Hospital Tuebingen | 66 | 2016-05-01 | 2018-06-26 |
| Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults PRIMVAC, GLA-SE, Alhydrogel - Malaria | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 68 | 2016-01-01 | 2025-12-04 |
| Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects AP10-602, GLA-SE, ID93 - Tuberculosis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 70 | 2015-10-22 | 2017-09-15 |
| MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis - Stage IIA Skin Melanoma, Stage IIB Skin Melanoma | Early Phase 1 | Completed | Mayo Clinic | 23 | 2015-01-27 | 2020-01-14 |
| TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Radiation Therapy, TLR4 Agonist GLA-SE - Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 16 | 2014-11-17 | 2019-11-06 |
| A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma GLA-SE - Merkel Cell Carcinoma | Phase 1 | Completed | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 10 | 2014-01-01 | 2018-06-13 |
| LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine GLA-SE, LEISH-F3, MPL-SE - Leishmaniasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2013-03-01 | 2017-01-02 |
| The Effects of GLA (5 mcg) on Human Volunteers GLA-AF, GLA-SE, EM060G (SE) - Healthy Volunteers | Phase 1 | Completed | Access to Advanced Health Institute (AAHI) | 17 | 2012-09-01 | 2014-02-26 |
| The Effects of GLA on Human Volunteers GLA-AF, GLA-SE, Squalene - Healthy Volunteers | Phase 1 | Completed | Rockefeller University | 32 | 2011-07-01 | 2013-09-23 |
Malaria (2) · Carcinoma, Merkel Cell (1) · Leishmaniasis (1) · Melanoma (1) · Sarcoma (1) · Tuberculosis (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Access to Advanced Health Institute (AAHI) (1) · Fred Hutchinson Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Mayo Clinic (1) · Rockefeller University (1) · University Hospital Tuebingen (1)
United States (7) · France (2) · Benin (1) · Burkina Faso (1)
Franco Piazza, MD, MPH (1) · Frank Hsu, MD (1) · Marina Caskey, MD (1) · Matthew Block (1) · Odile Launay, Professor (1) · Saadou Issifou, MD (1) · Seth Pollack (1)
PMID 33717176, PMID 30629148, PMID 30885725, PMID 32032566, PMID 32752904, PMID 33955240, PMID 34611164, PMID 35115306, PMID 37824131
2015 (1), 2017 (1), P30CA015083 (1), P30CA015704 (1)